Cargando…

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotei...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Yasunori, Berndsen, Zachary T., Raghwani, Jayna, Seabright, Gemma E., Allen, Joel D., Pybus, Oliver G., McLellan, Jason S., Wilson, Ian A., Bowden, Thomas A., Ward, Andrew B., Crispin, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253482/
https://www.ncbi.nlm.nih.gov/pubmed/32461612
http://dx.doi.org/10.1038/s41467-020-16567-0
_version_ 1783539341796048896
author Watanabe, Yasunori
Berndsen, Zachary T.
Raghwani, Jayna
Seabright, Gemma E.
Allen, Joel D.
Pybus, Oliver G.
McLellan, Jason S.
Wilson, Ian A.
Bowden, Thomas A.
Ward, Andrew B.
Crispin, Max
author_facet Watanabe, Yasunori
Berndsen, Zachary T.
Raghwani, Jayna
Seabright, Gemma E.
Allen, Joel D.
Pybus, Oliver G.
McLellan, Jason S.
Wilson, Ian A.
Bowden, Thomas A.
Ward, Andrew B.
Crispin, Max
author_sort Watanabe, Yasunori
collection PubMed
description Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66–87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface.
format Online
Article
Text
id pubmed-7253482
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72534822020-06-05 Vulnerabilities in coronavirus glycan shields despite extensive glycosylation Watanabe, Yasunori Berndsen, Zachary T. Raghwani, Jayna Seabright, Gemma E. Allen, Joel D. Pybus, Oliver G. McLellan, Jason S. Wilson, Ian A. Bowden, Thomas A. Ward, Andrew B. Crispin, Max Nat Commun Article Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66–87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface. Nature Publishing Group UK 2020-05-27 /pmc/articles/PMC7253482/ /pubmed/32461612 http://dx.doi.org/10.1038/s41467-020-16567-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Watanabe, Yasunori
Berndsen, Zachary T.
Raghwani, Jayna
Seabright, Gemma E.
Allen, Joel D.
Pybus, Oliver G.
McLellan, Jason S.
Wilson, Ian A.
Bowden, Thomas A.
Ward, Andrew B.
Crispin, Max
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
title Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
title_full Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
title_fullStr Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
title_full_unstemmed Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
title_short Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
title_sort vulnerabilities in coronavirus glycan shields despite extensive glycosylation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253482/
https://www.ncbi.nlm.nih.gov/pubmed/32461612
http://dx.doi.org/10.1038/s41467-020-16567-0
work_keys_str_mv AT watanabeyasunori vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT berndsenzacharyt vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT raghwanijayna vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT seabrightgemmae vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT allenjoeld vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT pybusoliverg vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT mclellanjasons vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT wilsoniana vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT bowdenthomasa vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT wardandrewb vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation
AT crispinmax vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation